PDE5 inhibitors: targeting erectile dysfunction in diabetics
Authors:
- Sharron H FrancisSFSharron H Francis
- Jackie D CorbinJCJackie D Corbin
- 1 December 2011
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 11 (6) , 683-688
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Relationship Between Erectile Dysfunction and Silent Myocardial Ischemia in Type 2 Diabetic Patients with No Known Macrovascular ComplicationsThe Journal of Sexual Medicine, 2011
- Five-Item Version of the International Index of Erectile Function Correlated with Albuminuria and Subclinical Atherosclerosis in Men with Type 2 DiabetesJournal of Atherosclerosis and Thrombosis, 2011
- cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP ActionPharmacological Reviews, 2010
- Chronic inhibition of nitric‐oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafilBJU International, 2010
- Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensusInternational Journal Of Clinical Practice, 2010
- Diabetes Exacerbates the Functional Deficiency of NO/cGMP Pathway Associated with Erectile Dysfunction in Human Corpus Cavernosum and Penile ArteriesThe Journal of Sexual Medicine, 2010
- Erectile Dysfunction in Diabetes MellitusThe Journal of Sexual Medicine, 2009
- Type 2 Diabetes Mellitus and Erectile DysfunctionThe Journal of Sexual Medicine, 2009
- Erectile Dysfunction as a Predictor of Cardiovascular Events and Death in Diabetic Patients With Angiographically Proven Asymptomatic Coronary Artery DiseaseJACC, 2008
- Phosphodiesterase-5 Inhibition: the Molecular Biology of Erectile Function and DysfunctionUrologic Clinics of North America, 2005